Boehringer Ingelheim Pharmaceuticals / J&J/Pfizer (US OTC Zantac rights)

Heartburn / Acid Reduction (OTC GERD-related symptoms)

Disease Overview

Heartburn and acid indigestion are highly prevalent self-treated symptoms tied to gastroesophageal reflux. The OTC H2 receptor antagonist category (Zantac, Pepcid, Tagamet) provided fast onset acid suppression for episodic relief, complementing OTC PPIs (Prilosec OTC, Nexium 24HR) for frequent heartburn.

Competitive Landscape

At the December 2006 close of the Boehringer Ingelheim-J&J/Pfizer deal, OTC Zantac (ranitidine) competed primarily with Pepcid AC/Pepcid Complete (famotidine; J&J McNeil), Tagamet HB (cimetidine; GSK), and store-brand H2 blockers, alongside the rapidly growing OTC PPI segment led by Prilosec OTC (P&G) and later Nexium 24HR (Pfizer). FTC required the Zantac divestiture to clear J&J's $16.6B acquisition of Pfizer's Consumer Healthcare unit because retaining both Pepcid AC and Zantac would have given J&J dominant share of the OTC H2 blocker category. For Boehringer Ingelheim, Zantac complemented Dulcolax to form a leading OTC GI portfolio in the US. The Zantac OTC asset was later acquired by Sanofi in 2017 and pulled from the US market in 2019-2020 after FDA found NDMA contamination in ranitidine products, triggering massive product liability litigation that has since dwarfed the original deal value.